DCAL2024-04-012024-06-30 DCAL2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member DCAL2024-06-30 DCAL2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DCAL2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DCAL2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member DCAL2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540701 DCAL NA Dishman Carbogen Amcis Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-07 INR Crores First quarter 14:00:00 20:15:00 2024-08-13 2024-08-13 Not applicable Single segment Contract Research and Manufacturing Services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc 2024-04-01 2024-06-30 Unaudited Standalone 1034100000.00 115900000.00 1150000000.00 322500000.00 0.00 92500000.00 229700000.00 157300000.00 163200000.00 240400000.00 1205600000.00 -55600000.00 0.00 -55600000.00 0.00 -20900000.00 -20900000.00 0.00 -34700000.00 0.00 0.00 0.00 0.00 -34700000.00 5500000.00 -29200000.00 0.00 0.00 313600000.00 2 -0.22 -0.22 0.00 0.00 -0.22 -0.22 0.00 0.01 0.02 Notes: 1. The Financial results (standalone and consolidated) have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 13th August 2024. 2. Statutory Auditors have carried out limited review of standalone as well as consolidated financial results of the Company for the first quarter ended 30th June 2024. Note: for full notes to FR, refer Quick Result Other Expenditures 240400000.00 Remeasurement gain/(losses) on defined benefit plans -200000.00 Income Tax effect on above 100000.00 Changes in fair value of FVTOCI equity instruments -100000.00 -200000.00 0.00 Foreign exchange fluctuations in respect of cash flow hedge 8700000.00 8700000.00 3000000.00